NASDAQ:IRD Opus Genetics 3/31/2025 Earnings Report $0.76 +0.02 (+3.39%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Opus Genetics EPS ResultsActual EPS-$1.27Consensus EPS -$0.34Beat/MissMissed by -$0.93One Year Ago EPSN/AOpus Genetics Revenue ResultsActual Revenue$3.40 millionExpected Revenue$11.10 millionBeat/MissMissed by -$7.70 millionYoY Revenue GrowthN/AOpus Genetics Announcement DetailsQuarterDate3/31/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsOpus Genetics' next earnings date is estimated for Friday, May 9, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Opus Genetics Earnings HeadlinesPRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George MagrathApril 15 at 6:56 PM | markets.businessinsider.comOpus Genetics (NASDAQ:IRD) Now Covered by Analysts at Craig HallumApril 14, 2025 | americanbankingnews.comTrump Orders 'National Digital Asset Stockpile'Trump's Tariff Pause Creates Crypto Gold Rush This opportunity could eclipse them all…April 18, 2025 | Crypto 101 Media (Ad)Craig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy RecommendationApril 12, 2025 | msn.comCraig-Hallum bullish on Opus Genetics, initiates with a BuyApril 11, 2025 | markets.businessinsider.comOpus Genetics initiated with a Buy at Craig-HallumApril 11, 2025 | markets.businessinsider.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
